ReviewTransplantation2009
Intravenous immunoglobulin a natural regulator of immunity and inflammation.
Review in Transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02130817 (Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function), which is not on this map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)
Who cites it
35 citing papers in PubMed, 111 citations in OpenAlex.
- 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study.Transplant international : official journal of the European Society for Organ Transplantation · 2025Trial
- Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives.Clinical kidney journal · 2025Review
- De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians.Journal of clinical medicine · 2023Review
- A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy.Frontiers in immunology · 2023Article
- The first clinical pig heart transplant: Was IVIg or pig cytomegalovirus detrimental to the outcome?Xenotransplantation · 2022Review
- Effects of glucose oxidase on growth performance, clinical symptoms, serum parameters, and intestinal health in piglets challenged by enterotoxigenicFrontiers in microbiology · 2022Article
- Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in liver transplantation.Annals of hepato-biliary-pancreatic surgery · 2021Article
- Plasma cell biology: Foundations for targeted therapeutic development in transplantation.Immunological reviews · 2021Review
- Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.Vaccines · 2021Review
- Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.Microorganisms · 2021Review
- SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.Transplant infectious disease : an official journal of the Transplantation Society · 2020Article
- Effect of intravenous immunoglobulin (IVIg) on primate complement-dependent cytotoxicity of genetically engineered pig cells: relevance to clinical xenotransplantation.Scientific reports · 2020Article
- Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.Immunotherapy · 2020Article
- Mortality of Chinese patients with polymyositis and dermatomyositis.Clinical rheumatology · 2020Article
- Desensitization: Overcoming the Immunologic Barriers to Transplantation.Journal of immunology research · 2017Review
- Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin.Human immunology · 2016Article
- Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.Scientific reports · 2016Article
- Intravenous immunoglobulin for antibody-mediated keratolimbal allograft rejection.BMJ case reports · 2015Article
- Establishment of HSV1 latency in immunodeficient mice facilitates efficient in vivo reactivation.PLoS pathogens · 2015Article
- Rational clinical trial design for antibody mediated renal allograft injury.Frontiers in bioscience (Landmark edition) · 2015Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 25 years. IVIG products are also effective in the treatment of autoimmune and inflammatory disorders; however, the precise mechanism(s) of action is not known. Recent investigations suggest that IVIG has a much broader ability to regulate cellular immunity including innate and adaptive components. IVIG is also a recently recognized modifier of complement activation and injury. Here, we discuss these important advancements and how this knowledge applies to desensitization protocols and to the treatment of antibody-mediated rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.